Reports Q4 revenue $765K, consensus $760k. "2022 was a pivotal year for Singular Genomics. It was a year in which we achieved important milestones, overcame challenges, and ultimately ended on a strong note with five G4 systems in market. Most importantly, the business is set up for success with the right team, the right product, and the right opportunity. I am tremendously proud of the entire Singular team," said Drew Spaventa, Chairman and Chief Executive Officer of Singular Genomics. "In 2023, we will remain focused on customer success across a growing installed base, commercial and operational execution, and advancing our innovation pipeline."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on OMIC:
- Singular Genomics Reports Recent Highlights and Fourth Quarter and Full Year 2022 Financial Results
- Singular Genomics to Present at Cowen’s 43rd Annual Health Care Conference
- Singular Genomics to Report Fourth Quarter 2022 Financial Results on March 2, 2023
- Singular Genomics announces launch of Max Read Kits
- Singular Genomics showcases G4 sequencing data with 11 genomics partners
